Specialized Research Khavinson Bioregulator

Vilon

Also known as: Peptídeo retinal

Molecular Identifiers

Molecular Formula

C11H21N3O5

PubChem CID

7010502

Molecular Weight

275.30 Da

Overview

Immunological and retinal bioregulatory dipeptide developed by the Khavinson group. The smallest bioactive peptide in its class, it modulates gene expression in immune and retinal tissues. Used in short cycles for immune support and retinal protection.

Sequence (1 letter): KE
Extended notation: Lys-Glu

Half-life

~2-4 hours

Administration Route

Subcutaneous or intramuscular

Category

Specialized Research

Mechanism of Action

  • Modulation of gene expression in immune cells
  • Support for retinal tissue function and integrity
  • Regulation of lymphocyte differentiation and activity
  • Normalization of innate immune response
  • Peptide bioregulatory effect on the immune system and retina

Dosage Protocol

Data compiled from the literature. This does not constitute medical advice.

Parameter Value
Dose 5-10 mg per day subcutaneously
Frequency Once daily
Timing Morning or as per protocol
Duration 10-20 days, cycled 2-4 times per year

Reported Side Effects

Adverse effects described in the literature. Severity and frequency vary between individuals.

  • Injection site pain
  • Local redness (rare)

Presentations & Preparation

Vials of Vilon found in the research market:

20 mg

Reconstitution

  • Diluent: Bacteriostatic water
  • Volume: 2 ml per vial
  • Slowly inject the diluent against the vial wall
  • Gently swirl until fully dissolved
  • Never shake

Storage

  • Lyophilized: Refrigerated 2-8°C
  • Reconstituted: Refrigerated 2-8°C (up to 30 days)
  • Protect from direct light
  • Do not freeze after reconstitution
Reconstitution Calculator

Scientific Studies

Published studies on Vilon.

2003 · Neuro Endocrinol Lett

Peptides of pineal gland and thymus prolong human life

Khavinson VKh, Morozov VG
2022 · Int J Mol Sci

Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line

Avolio F, Martinotti S, Khavinson VKh, Esposito JE, Giambuzzi G, Marino A, et al.

Related Peptides

Aviptadil

50-150 mcg per administration (IV or subcutaneous) · 1-3 times daily per protocol

B7-33

100-500 mcg per injection (subcutaneous) · Once daily

Bronchogen

5-10 mg per day via subcutaneous injection · Once daily

Cardiogen

5-10 mg per day subcutaneously · Once daily

Chonluten

5-10 mg per day subcutaneously · Once daily

Crystagen

5-10 mg per day via subcutaneous injection · Once daily